{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:13:31Z","timestamp":1782969211448,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bone marrow (BM) angiogenesis significantly influences disease progression in multiple myeloma (MM) patients and correlates with adverse prognosis. The present study shows a statistically significant correlation of the AP-1 family member JunB with VEGF, VEGFB, and IGF1 expression levels in MM. In contrast to the angiogenic master regulator Hif-1\u03b1, JunB protein levels were independent of hypoxia. Results in tumor-cell models that allow the induction of JunB knockdown or JunB activation, respectively, corroborated the functional role of JunB in the production and secretion of these angiogenic factors (AFs). Consequently, conditioned media derived from MM cells after JunB knockdown or JunB activation either inhibited or stimulated in vitro angiogenesis. The impact of JunB on MM BM angiogenesis was finally confirmed in a dynamic 3D model of the BM microenvironment, a xenograft mouse model as well as in patient-derived BM sections. In summary, in continuation of our previous study (Fan et al., 2017), the present report reveals for the first time that JunB is not only a mediator of MM cell survival, proliferation, and drug resistance, but also a promoter of AF transcription and consequently of MM BM angiogenesis. Our results thereby underscore worldwide efforts to target AP-1 transcription factors such as JunB as a promising strategy in MM therapy.<\/jats:p>","DOI":"10.1038\/s41375-021-01271-9","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T09:02:53Z","timestamp":1621328573000},"page":"3509-3525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["JunB is a key regulator of multiple myeloma bone marrow angiogenesis"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8727-5258","authenticated-orcid":false,"given":"Fengjuan","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Malvestiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Vallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Garcia-Manteiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8850-0442","authenticated-orcid":false,"given":"Eugenio","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyue","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8348-2620","authenticated-orcid":false,"given":"Andreas","family":"Stadlbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-2443","authenticated-orcid":false,"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pecherstorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6300-2420","authenticated-orcid":false,"given":"Latifa","family":"Bakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-0196","authenticated-orcid":false,"given":"Erwin F.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2973-5038","authenticated-orcid":false,"given":"Giovanni","family":"Tonon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-4568","authenticated-orcid":false,"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7414-3632","authenticated-orcid":false,"given":"Klaus","family":"Podar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"1271_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/sj.leu.2404067","volume":"20","author":"A Vacca","year":"2006","unstructured":"Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia. 2006;20:193\u20139.","journal-title":"Leukemia"},{"key":"1271_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","volume":"87","author":"A Vacca","year":"1994","unstructured":"Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87:503\u20138.","journal-title":"Br J Haematol"},{"key":"1271_CR3","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1182\/blood-2003-04-1338","volume":"102","author":"A Vacca","year":"2003","unstructured":"Vacca A, Ria R, Semeraro F, Merchionne F, Coluccia M, Boccarelli A, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood. 2003;102:3340\u20138.","journal-title":"Blood"},{"key":"1271_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/jmri.20349","volume":"22","author":"S Nos\u00e0s-Garcia","year":"2005","unstructured":"Nos\u00e0s-Garcia S, Moehler T, Wasser K, Kiessling F, Bartl R, Zuna I, et al. Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers. J Magn Reson Imaging. 2005;22:154\u201362.","journal-title":"J Magn Reson Imaging"},{"key":"1271_CR5","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood.V93.9.3064.409k07_3064_3073","volume":"93","author":"A Vacca","year":"1999","unstructured":"Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064\u201373.","journal-title":"Blood"},{"key":"1271_CR6","first-page":"3111","volume":"6","author":"SV Rajkumar","year":"2000","unstructured":"Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6:3111\u20136.","journal-title":"Clin Cancer Res"},{"key":"1271_CR7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1046\/j.1365-2141.2002.03871.x","volume":"119","author":"S Kumar","year":"2002","unstructured":"Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol. 2002;119:665\u201371.","journal-title":"Br J Haematol"},{"key":"1271_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1158\/1078-0432.CCR-06-0061","volume":"13","author":"J Hillengass","year":"2007","unstructured":"Hillengass J, Wasser K, Delorme S, Kiessling F, Zechmann C, Benner A, et al. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma. Clin Cancer Res. 2007;13:475\u201381.","journal-title":"Clin Cancer Res"},{"key":"1271_CR9","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood-2003-11-3811","volume":"104","author":"S Kumar","year":"2004","unstructured":"Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood. 2004;104:1159\u201365.","journal-title":"Blood"},{"key":"1271_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood-2008-10-184226","volume":"114","author":"D Hose","year":"2009","unstructured":"Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009;114:128\u201343.","journal-title":"Blood"},{"key":"1271_CR11","doi-asserted-by":"publisher","unstructured":"Podar K, Anderson KC. Targeting multiple myeloma tumor angiogenesis: focus on VEGF. 2013. https:\/\/doi.org\/10.1007\/978-1-4614-4666-8_15.","DOI":"10.1007\/978-1-4614-4666-8_15"},{"key":"1271_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/sj.bmt.1704555","volume":"34","author":"S Kumar","year":"2004","unstructured":"Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transpl. 2004;34:235\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"1271_CR13","first-page":"2675","volume":"7","author":"K Neben","year":"2001","unstructured":"Neben K, Moehler T, Egerer G, Kraemer A, Hillengass J, Benner A, et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res. 2001;7:2675\u201381.","journal-title":"Clin Cancer Res"},{"key":"1271_CR14","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/sj.leu.2403285","volume":"18","author":"S Kumar","year":"2004","unstructured":"Kumar S, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia. 2004;18:624\u20137.","journal-title":"Leukemia"},{"key":"1271_CR15","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1271_CR16","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565\u201371.","journal-title":"N Engl J Med"},{"key":"1271_CR17","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2174\/156800911798073113","volume":"11","author":"K Podar","year":"2011","unstructured":"Podar K, Anderson KC. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Curr Cancer Drug Targets. 2011;11:1005\u201324.","journal-title":"Curr Cancer Drug Targets"},{"key":"1271_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/emboj\/18.4.934","volume":"18","author":"M Schorpp-Kistner","year":"1999","unstructured":"Schorpp-Kistner M, Wang ZQ, Angel P, Wagner EF. JunB is essential for mammalian placentation. EMBO J. 1999;18:934\u201348.","journal-title":"EMBO J"},{"key":"1271_CR19","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1038\/onc.2011.475","volume":"31","author":"T Kanno","year":"2012","unstructured":"Kanno T, Kamba T, Yamasaki T, Shibasaki N, Saito R, Terada N, et al. JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma. Oncogene. 2012;31:3098\u2013110.","journal-title":"Oncogene"},{"key":"1271_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/path.2484","volume":"217","author":"Y Reiss","year":"2009","unstructured":"Reiss Y, Knedla A, Tal AO, Schmidt MHH, Jugold M, Kiessling F, et al. Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2. J Pathol. 2009;217:571\u201380.","journal-title":"J Pathol"},{"key":"1271_CR21","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/leu.2016.358","volume":"31","author":"F Fan","year":"2017","unstructured":"Fan F, Bashari MH, Morelli E, Tonon G, Malvestiti S, Vallet S, et al. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. Leukemia. 2017;31:1570\u201381.","journal-title":"Leukemia"},{"key":"1271_CR22","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1093\/emboj\/19.9.2056","volume":"19","author":"L Bakiri","year":"2000","unstructured":"Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 2000;19:2056\u201368.","journal-title":"EMBO J"},{"key":"1271_CR23","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.1158\/0008-5472.CAN-08-4603","volume":"69","author":"J Zhang","year":"2009","unstructured":"Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, Zimmerhackl A, et al. Targeting angiogenesis via a c-Myc\/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res. 2009;69:5082\u201390.","journal-title":"Cancer Res"},{"key":"1271_CR24","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109:1692\u2013700.","journal-title":"Blood"},{"key":"1271_CR25","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020\u20138.","journal-title":"Blood"},{"key":"1271_CR26","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1158\/0008-5472.CAN-06-4046","volume":"67","author":"WJ Chng","year":"2007","unstructured":"Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007;67:2982\u20139.","journal-title":"Cancer Res"},{"key":"1271_CR27","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Pro Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Pro Natl Acad Sci USA"},{"key":"1271_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"1271_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jan\u00e9-Valbuena J, Kryukov GV, Lo CC, McDonald ER, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569:503\u20138.","journal-title":"Nature"},{"key":"1271_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00380-3","volume":"8","author":"TM Carr","year":"2017","unstructured":"Carr TM, Wheaton JD, Houtz GM, Ciofani M. JunB promotes Th17 cell identity and restrains alternative CD4+ T-cell programs during inflammation. Nat Commun. 2017;8:301.","journal-title":"Nat Commun"},{"key":"1271_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.","journal-title":"Nat Commun"},{"key":"1271_CR32","doi-asserted-by":"crossref","first-page":"D87","DOI":"10.1093\/nar\/gkaa516","volume":"48","author":"O Fornes","year":"2020","unstructured":"Fornes O, Castro-Mondragon JA, Khan A, van der Lee R, Zhang X, Richmond PA, et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2020;48:D87\u201392.","journal-title":"Nucleic Acids Res"},{"key":"1271_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/bioinformatics\/18.2.333","volume":"18","author":"X Messeguer","year":"2002","unstructured":"Messeguer X, Escudero R, Farr\u00e9 D, N\u00fa\u00f1ez O, Mart\u00ednez J, Alb\u00e0 MM. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002;18:333\u20134.","journal-title":"Bioinformatics"},{"key":"1271_CR34","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1093\/nar\/gkg605","volume":"31","author":"D Farr\u00e9","year":"2003","unstructured":"Farr\u00e9 D, Roset R, Huerta M, Adsuara JE, Rosell\u00f3 L, Alb\u00e0 MM, et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 2003;31:3651\u20133.","journal-title":"Nucleic Acids Res"},{"key":"1271_CR35","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607\u201313.","journal-title":"Nucleic Acids Res"},{"key":"1271_CR36","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504.","journal-title":"Genome Res"},{"key":"1271_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-4-2","volume":"4","author":"GD Bader","year":"2003","unstructured":"Bader GD, Hogue CWV. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinforma. 2003;4:2.","journal-title":"BMC Bioinforma"},{"key":"1271_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28699-x","volume":"8","author":"M Persson","year":"2018","unstructured":"Persson M, Lehenkari PP, Berglin L, Turunen S, Finnil\u00e4 MAJ, Risteli J, et al. Osteogenic differentiation of human mesenchymal stem cells in a 3D woven scaffold. Sci Rep. 2018;8:10457.","journal-title":"Sci Rep"},{"key":"1271_CR39","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"1271_CR40","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/leu.2009.130","volume":"23","author":"M Roussou","year":"2009","unstructured":"Roussou M, Tasidou A, Dimopoulos MA, Kastritis E, Migkou M, Christoulas D, et al. Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia. 2009;23:2177\u201381.","journal-title":"Leukemia"},{"key":"1271_CR41","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00277-010-0919-z","volume":"89","author":"C Rana","year":"2010","unstructured":"Rana C, Sharma S, Agrawal V, Singh U. Bone marrow angiogenesis in multiple myeloma and its correlation with clinicopathological factors. Ann Hematol. 2010;89:789\u201394.","journal-title":"Ann Hematol"},{"key":"1271_CR42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"1271_CR43","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/nature03703","volume":"435","author":"DA Sipkins","year":"2005","unstructured":"Sipkins DA, Wei X, Wu JW, Runnels JM, C\u00f4t\u00e9 D, Means TK, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005;435:969\u201373.","journal-title":"Nature"},{"key":"1271_CR44","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","volume":"2","author":"L Schito","year":"2016","unstructured":"Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer. 2016;2:758\u201370.","journal-title":"Trends Cancer"},{"key":"1271_CR45","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","volume":"119","author":"AK Azab","year":"2012","unstructured":"Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012;119:5782\u201394.","journal-title":"Blood"},{"key":"1271_CR46","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/leu.2013.24","volume":"27","author":"P Storti","year":"2013","unstructured":"Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, et al. Hypoxia-inducible factor (HIF)-1\u03b1 suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia. 2013;27:1697\u2013706.","journal-title":"Leukemia"},{"key":"1271_CR47","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1038\/leu.2010.193","volume":"24","author":"S Colla","year":"2010","unstructured":"Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M, et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1\u03b1 overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia. 2010;24:1967\u201370.","journal-title":"Leukemia"},{"key":"1271_CR48","doi-asserted-by":"publisher","unstructured":"Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, Zimmerhackl A, et al. Targeting angiogenesis via a c-Myc\/hypoxia-inducible factor-1\u03b1-dependent pathway in multiple myeloma. Cancer Res. 2009;69. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4603.","DOI":"10.1158\/0008-5472.CAN-08-4603"},{"key":"1271_CR49","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1182\/blood-2010-02-269126","volume":"116","author":"J Hu","year":"2010","unstructured":"Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood. 2010;116:1524\u20137.","journal-title":"Blood"},{"key":"1271_CR50","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/leu.2010.270","volume":"25","author":"P Storti","year":"2011","unstructured":"Storti P, Donofrio G, Colla S, Airoldi I, Bolzoni M, Agnelli L, et al. HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia. 2011;25:527\u201337.","journal-title":"Leukemia"},{"key":"1271_CR51","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33:3911\u201320.","journal-title":"J Clin Oncol"},{"key":"1271_CR52","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","volume":"9","author":"DR Carrasco","year":"2006","unstructured":"Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9:313\u201325.","journal-title":"Cancer Cell"},{"key":"1271_CR53","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"I Hanamura","year":"2006","unstructured":"Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108:1724\u201332.","journal-title":"Blood"},{"key":"1271_CR54","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699","volume":"88","author":"P Liu","year":"1996","unstructured":"Liu P, Leong T, Quam L, Billaud J-N, Kay NE, Greipp P, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III trial. Blood. 1996;88:2699\u2013706.","journal-title":"Blood"},{"key":"1271_CR55","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1084\/jem.170.5.1715","volume":"170","author":"A Neri","year":"1989","unstructured":"Neri A, Murphy JP, Cro L, Ferrero D, Tarella C, Baldini L, et al. Ras oncogene mutation in multiple myeloma. J Exp Med. 1989;170:1715\u201325.","journal-title":"J Exp Med"},{"key":"1271_CR56","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1182\/blood.V81.10.2708.2708","volume":"81","author":"P Corradini","year":"1993","unstructured":"Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles DM, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood. 1993;81:2708\u201313.","journal-title":"Blood"},{"key":"1271_CR57","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/humu.1177","volume":"18","author":"S Bezieau","year":"2001","unstructured":"Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat. 2001;18:212\u201324.","journal-title":"Hum Mutat"},{"key":"1271_CR58","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrg1315","volume":"5","author":"WW Wasserman","year":"2004","unstructured":"Wasserman WW, Sandelin A. Applied bioinformatics for the identification of regulatory elements. Nat Rev Genet. 2004;5:276\u201387.","journal-title":"Nat Rev Genet"},{"key":"1271_CR59","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40484-013-0012-4","volume":"1","author":"GD Stormo","year":"2013","unstructured":"Stormo GD. Modeling the specificity of protein-DNA interactions. Quant Biol. 2013;1:115\u201330.","journal-title":"Quant Biol"},{"key":"1271_CR60","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/978-1-4939-7021-6_13","volume":"1612","author":"M Ferrarini","year":"2017","unstructured":"Ferrarini M, Steimberg N, Boniotti J, Berenzi A, Belloni D, Mazzoleni G, et al. 3D-dynamic culture models of multiple myeloma. Methods Mol Biol. 2017;1612:177\u201390.","journal-title":"Methods Mol Biol"},{"key":"1271_CR61","doi-asserted-by":"publisher","unstructured":"Papadimitriou K, Kostopoulos IV, Tsopanidou A, Orologas-Stavrou N, Kastritis E, Tsitsilonis O, et al. Ex vivo models simulating the bone marrow environment and predicting response to therapy in multiple myeloma. Cancers (Basel). 2020;12. https:\/\/doi.org\/10.3390\/cancers12082006.","DOI":"10.3390\/cancers12082006"},{"key":"1271_CR62","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/leu.2010.300","volume":"25","author":"T Calimeri","year":"2011","unstructured":"Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, Rossi M, et al. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia. 2011;25:707\u201311.","journal-title":"Leukemia"},{"key":"1271_CR63","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/sj.emboj.7601539","volume":"26","author":"D Schmidt","year":"2007","unstructured":"Schmidt D, Textor B, Pein OT, Licht AH, Andrecht S, Sator-Schmitt M, et al. Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J. 2007;26:710\u20139.","journal-title":"EMBO J"},{"key":"1271_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.36","volume":"6","author":"J Xu","year":"2017","unstructured":"Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah NH, Lehners N, et al. Molecular signaling in multiple myeloma: association of RAS\/RAF mutations and MEK\/ERK pathway activation. Oncogenesis. 2017;6:e337.","journal-title":"Oncogenesis"},{"key":"1271_CR65","doi-asserted-by":"publisher","first-page":"6930","DOI":"10.1021\/jm5004733","volume":"57","author":"N Ye","year":"2014","unstructured":"Ye N, Ding Y, Wild C, Shen Q, Zhou J. Small molecule inhibitors targeting activator protein 1 (AP-1). J Med Chem. 2014;57:6930\u201348.","journal-title":"J Med Chem"},{"key":"1271_CR66","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","volume":"4","author":"X Sun","year":"2019","unstructured":"Sun X, Gao H, Yang Y, He M, Wu Y, Song Y, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019;4:64.","journal-title":"Signal Transduct Target Ther"},{"key":"1271_CR67","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/13543784.2019.1605354","volume":"28","author":"S Li","year":"2019","unstructured":"Li S, Vallet S, Sacco A, Roccaro A, Lentzsch S, Podar K. Targeting transcription factors in multiple myeloma: evolving therapeutic strategies. Expert Opin Investig Drugs. 2019;28:445\u201362.","journal-title":"Expert Opin Investig Drugs"}],"updated-by":[{"DOI":"10.1038\/s41375-021-01367-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01271-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01271-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01271-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T08:03:57Z","timestamp":1675325037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01271-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1271"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01271-9","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41375-021-01367-2","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"14 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-021-01367-2","URL":"https:\/\/doi.org\/10.1038\/s41375-021-01367-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SV received speaker\u2019s honoraria from Bristol Myers Squibb, MSD, Pfizer, and consultancy fees from Roche, Eusa, MSD, and Merck. DJ received consultant honoraria from Bayer, Amgen, MSD, CureVac, Roche, and BMS. KP has received speaker\u2019s honoraria from Celgene, Amgen Inc., and Janssen Pharmaceuticals, consultancy fees from Celgene, Takeda, and Janssen Pharmaceuticals, and research support from Roche Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}